VCAM-targeted delivery of recombinant CD39 to the endothelium is antithrombotic, antiinflammatory and ameliorates ischaemia reperfusion injury

Project: Research

StatusFinished
Effective start/end date1/01/1531/12/18

Funding

  • National Health & Medical Research Council (NHMRC): AUD603,813.00